Bone marrow transplantation (BMT) is increasingly used in an attempt to correct inborn errors of metabolism (IEM). However, little is known about effects of BMT from patients with IEM donating for non-affected recipients. We present data from a 8.5-year-old girl who underwent BMT in second remission for relapsed acute lymphoblastic leukaemia (ALL) at the age of 7 years from her HLA-identical brother who was severely affected by Hunter syndrome (Mucopolysaccharidosis type II, iduronate-2-sulphatase (IDS) deficiency). After BMT not only leukocyte but also plasma activity of IDS was absent. Mixing experiments and immunoadsorption suggest antibody-mediated enzyme inhibition. However, her urinary glycosaminoglycan excretion has not increased post BMT and clinical signs of mucopolysaccharidosis are absent 20 months after BMT. We conclude that patients with white cell enzyme deficiencies and other IEMs do not have to be excluded from bone marrow donation. Antibody production by the graft may occur and be reflected by a marked reduction in plasma enzyme levels but not tissue activity. Similar antibody responses resulting in enzyme inactivation might also affect other enzyme replacement strategies for individuals with IEM. Bone Marrow Transplantation (2000) 25, 909-911.
and MPS type III (Sanfilippo syndrome), despite apparent biochemical correction in peripheral plasma, BMT does not seem to alter the clinical course compared with untreated individuals in terms of central nervous system progression. 2, 4, 5 However, little is known about biochemical or clinical effects of enzyme-deficient marrow transplanted into non-deficient recipients, as to our knowledge bone marrow from patients with inborn errors of metabolism has not been transplanted into unaffected individuals. Here, we report the case of a girl who underwent BMT for common acute lymphoblastic leukaemia in second remission. She had a sibling BMT from her HLA-identical older brother who is severely affected by Hunter syndrome, IDS deficiency. We describe the clinical and biochemical observations and discuss clinical implications.
Case report
A 4.5-year-old girl was diagnosed as having common acute lymphoblastic leukaemia. She is the youngest of three siblings of a healthy Caucasian couple. The two 18 and 30 months older brothers are both severely affected by Hunter syndrome, MPS type II, IDS deficiency. She was known to be a carrier for the condition. She received chemotherapy according to the UKALL XI protocol with an uncomplicated remission induction. Maintenance chemotherapy was complicated by measles contact and completed 22 months after diagnosis. Eleven months off treatment, aged 7.1 years, she suffered an isolated bone marrow relapse of her acute lymphoblastic leukaemia and received re-induction chemotherapy according to the MRC relapsed ALL protocol (R2). In second remission the family was tissue typed to explore the possibility of a family bone marrow donor. Her 18 months older brother, severely affected by MPS II, was found to be HLA identical.
Initially, it was considered not to be ethically justifiable to harvest bone marrow from the sibling with Hunter syndrome because of the high risk of general anaesthesia in patients with mucopolysaccharide disorders. 6, 7 Subsequently, however, the brother required surgery for a large umbilical hernia and at the time of this surgery bone marrow was harvested for transplantation.
At the age of 7.5 years the girl underwent sibling BMT in second remission from ALL. She was conditioned for BMT using total body irradiation (TBI) and cyclophosphamide. Graft-versus-host disease (GVHD) prophylaxis with cyclosporin A was started on day ϩ1. The girl had an uncomplicated post-transplant period with only mild acute GVHD. By day 14 she was transfusion independent and fully engrafted, as demonstrated by cytogenetics and by variable number tandem repeat (VNTR) PCR.
As expected, white cell IDS activity was absent shortly after BMT. Interestingly, however, by day ϩ20 post BMT plasma IDS activity was also significantly decreased and later became absent (Figure 1 ). This was not expected, as IDS is secreted into plasma by the liver. Therefore, further investigations were undertaken. Mixing patient plasma (IDS-activity 0 nmol/h/ml) with plasma from another patient post BMT for leukaemia (chosen because this control was on the same drug regimen as the patient and had equally low white cell counts) with IDS activity of 2.54 nmol/h/ml) 1:1 (vol:vol), resulted in a mixed plasma IDS activity of only 0.62 nmol/h/ml and not 1.72 nmol/h/ml as predicted. Table 1 shows the results of mixing experiments also involving serum from an IDS-deficient individual (unfortunately plasma from the donor was not available) and a normal child. ␤-hexosaminidase activity was used as control enzyme activity. Only IDS activity is inhibited by mixing with the patient's plasma. ␤-Hexosaminidase Table 1 Enzyme 
IDS activity in bold expressed as nmol/h/ml (␤-hexosamonidase activity in nmol/h/ml in brackets as control enzyme).
activity is unaffected with mixed plasma activity very near predicted values. No inhibitory effect is observed mixing control plasma with plasma from an individual with IDS deficiency. After adsorption with protein G-sepharose, the inhibitory effect of patient plasma was lost and IDS activity in the patients plasma recovered to 0.36 nmol/h/ml. These studies indicate that the inhibition was immunologically mediated and the BMT recipient's plasma contains an antibody against IDS. Despite absent white cell and plasma IDS activity, however, urinary glycosaminoglycan excretion (measured as dimethylmethylene blue/creatinine ratio mg/mmol 8 ) has not increased and continues to be within the age-dependent normal range (Ͻ15 mg/mmol) in the patient (Figure 2) .
Clinically, the patient is well 20 months post BMT. There is no evidence of leukaemic relapse and no GVHD. There is no clinical evidence of IDS deficiency.
Discussion
In a clinical situation where sibling BMT was indicated for the treatment of relapsed ALL, we used the iduronate-2-sulphatase-deficient brother as the bone marrow donor. To our knowledge, there have been no reported cases of individuals with IEM who have donated bone marrow for transplantation. The clinical and biochemical findings of the transplanted patient raise three very important issues.
Firstly, the BMT recipient shows no clinical signs or biochemical evidence of MPS II from urinary glycosaminoglycan studies, suggesting adequate residual tissue IDS activity. Therefore, we conclude that individuals with IEM do not have to be excluded from bone marrow donation per se.
Secondly, the early decrease and continuing absence of plasma IDS activity appears to be antibody mediated as suggested by mixing experiments and partial enzyme recovery after immuno-adsorption. As one control serum originated from another post-BMT patient, it is unlikely that drugs such as cyclosporin A could have interfered with the IDS assay. Antibody production by the graft is normally difficult to detect in the early phase post BMT, but never- theless, might be of clinical importance with regard to short-and long-term effects of BMT.
Finally and most importantly, evidence of antibodymediated inhibition of plasma enzyme activity -in this case by the graft -may have wide clinical implications with regard to other methods of enzyme replacement in IEMaffected individuals. In the usual situation where an enzyme-deficient IEM patient is undergoing allogeneic BMT, the donor's full immunocompetence is also grafted into the patient. Therefore, the transplanted enzyme is not recognised as antigenic and anti-enzyme antibodies are not induced. In this present case the immune system of a deficient donor has been transplanted into an enzyme producing individual. Within 3 weeks circulating enzyme activity had been almost entirely lost due to antibody generation by the graft. The same phenomenon of enzyme inhibition has been reported in three MPS I-affected children auto-transplanted with genetically manipulated own bone marrow corrected for ␣-iduronidase deficiency (Hurler syndrome). 9 These patients also developed antibodies to the 'foreign' enzyme early in the post-transplant period resulting in loss of plasma activity, as their immune response was not manipulated at the same time. We conclude that the antigenetic potential of the deficient enzyme 'foreign' to the deficient individual's immune system resulting in antibody-mediated enzyme inhibition, may potentially affect the success of other enzyme replacement strategies designed as therapeutic approaches for children severely affected by inborn errors of metabolism.
